Majors Brian S, Arden Nilou, Oyler George A, Chiang Gisela G, Pederson Nels E, Betenbaugh Michael J
Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, 221 Maryland Hall, Baltimore, MD 21218-2694, USA.
J Biotechnol. 2008 Nov 25;138(3-4):103-6. doi: 10.1016/j.jbiotec.2008.08.003. Epub 2008 Aug 20.
The cell density is an inherent constraint in commercial mammalian cell cultures. Here, we describe a cell engineering strategy utilizing the overexpression of the E2F-1 cell cycle transcription factor in CHO DG44 cells that produce a monoclonal antibody in serum-free, suspension culture. Stable pools and cell lines expressing E2F-1 were isolated that attained viable cell densities 20% higher than control cell lines and continued proliferation for an additional day in batch culture. There were no significant changes in antibody production, apoptosis, and cell cycle compared to control cells, nor were the growth effects evident in fed-batch conditions. Overall, E2F-1 overexpression postponed entry into stationary phase in mammalian cells, but perhaps novel E2F-1 variants or combination cell cycle engineering strategies will be necessary to realize significant growth benefits in commercial applications.
细胞密度是商业哺乳动物细胞培养中的一个内在限制因素。在此,我们描述了一种细胞工程策略,该策略利用E2F-1细胞周期转录因子在无血清悬浮培养中产生单克隆抗体的CHO DG44细胞中的过表达。分离出表达E2F-1的稳定细胞库和细胞系,其活细胞密度比对照细胞系高20%,并在分批培养中继续增殖一天。与对照细胞相比,抗体产生、细胞凋亡和细胞周期没有显著变化,在补料分批培养条件下生长效应也不明显。总体而言,E2F-1过表达延缓了哺乳动物细胞进入稳定期,但可能需要新的E2F-1变体或联合细胞周期工程策略才能在商业应用中实现显著的生长效益。